Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease.
about
Managing hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: latest evidence and clinical usefulnessHyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherenceIs there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysisRisk factors of one year increment of coronary calcifications and survival in hemodialysis patientsVitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.When there will never be a randomized controlled trial.Predicting hospital cost in CKD patients through blood chemistry valuesEvaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerabilityIntegrative biology identifies shared transcriptional networks in CKD.Relationship between Fibroblast Growth Factor-23 and Mineral Metabolism in Chronic Kidney DiseaseMineral metabolism and outcomes in chronic kidney disease stage 2-4 patients.Pulmonary hypertension: epidemiology in different CKD stages and its association with cardiovascular morbidityParathyroidectomy improves survival in patients with severe hyperparathyroidism: a comparative studyIncreased arterial stiffness after coronary artery revascularization correlates with serious coronary artery lesions and poor clinical outcomes in patients with chronic kidney diseasePotentially modifiable factors associated with non-adherence to phosphate binder use in patients on hemodialysisCarotid, aorta and renal arteries intima-media thickness in patients with sporadic idiopathic hypoparathyroidism.Mineral metabolism markers and the long-term risk of hip fracture: the cardiovascular health study.Effect of High-Flux Dialysis on Circulating FGF-23 Levels in End-Stage Renal Disease Patients: Results from a Randomized Trial.Kinetic model of phosphorus mobilization during and after short and conventional hemodialysisFerric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data.Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysisCardiorenal Syndrome and the Role of the Bone-Mineral Axis and AnemiaEffects of lanthanum carbonate versus calcium carbonate on vascular stiffness and bone mineral metabolism in hemodialysis patients with type 2 diabetes mellitus: a randomized controlled trial.High Serum Phosphorus Level Is Associated with Left Ventricular Diastolic Dysfunction in Peritoneal Dialysis PatientsReduced Stroke Risk After Parathyroidectomy in End-Stage Renal Disease: A 13-Year Population-Based Cohort Study.To assess vascular calcification in the patients of hypoparathyroidism using multidetector computed tomography scan.Relationship of serum fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women.Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional linksSerum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction.A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study.Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all-cause mortality.Mechanisms for increased cardiovascular disease in chronic kidney dysfunction.Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease.Loss of function of Slc20a2 associated with familial idiopathic Basal Ganglia calcification in humans causes brain calcifications in mice.Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement.Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges.Perioperative management of the hemodialysis patient.Mineral metabolism and vitamin D in chronic kidney disease--more questions than answers.Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications.
P2860
Q26786000-8F8081FE-BB5F-4212-9C4C-F638677500ABQ26830013-9A91471C-40FD-4B25-90F3-1C422A351A31Q27011288-1105612D-5EE2-4233-AEFC-62699D9F7BE0Q33611410-895EF9CC-0EE2-4999-B738-CC257CC21F54Q33703957-D88CF382-0DAE-48FD-9DF9-BB6BEBEF5F82Q33894084-08D01D37-D053-42F2-B02B-AB423D68CD92Q34088691-A7A70544-7149-4D2D-853C-C6B723CA84C9Q34213692-1BB6B5EE-80FF-44B1-B98C-1552D8D04186Q34427636-2B760273-1BE5-4CB8-AE56-EECFF89F9B50Q34479134-82249343-2E40-4F64-9541-310146A71CFDQ34550213-7EDA4E6C-F89A-4283-B613-FFF47F278BE5Q34744209-21D11F74-97BF-4273-AC34-F8F015D11A26Q34934411-1DE1FAD3-EBAA-4277-A0E8-F9995B0349C9Q34985324-F6777800-5A11-4529-B2F4-66A1413BC03BQ35007369-A65E6BE5-72C0-4AB4-B51B-CA4D61D086C0Q35056366-896C7AF4-86B6-47F6-AC2F-DD680A9B31A8Q35101778-35765C94-62DD-416F-94A8-9ADCE7B8C0D9Q35646353-E216480F-8238-4E8A-9353-75A2724775B9Q35664616-F683095D-E351-40C3-964B-71E98F4568DDQ35736620-AF473536-5EF0-4303-82D1-65D0B35EB243Q35804097-71EDF659-C7A1-4183-A36B-560106EC19A5Q35893998-797FE6A4-BCAF-44D5-8391-ED9D30059D37Q36010396-3598985E-BAAA-475F-B659-C86BC2E80477Q36142874-FE37AB2A-848B-4200-84B6-5BA1151F1483Q36194208-7303AB04-E236-458D-9039-97DA7614AF3EQ36358016-C4D29726-5709-4809-AFD3-F571D54CEB34Q36364305-D90ADDD0-9C05-405B-820E-7D67D0E8D13FQ36648170-0F93C861-7AAE-4F74-8172-38EB58656103Q36880126-91A74AA9-D9EC-4AF3-8C8C-9E7EB52D4C0FQ37162734-D2EAD750-8EDE-4970-A895-C41C22AA2B09Q37204047-6C9E0B65-83AD-4EBF-9AEA-1AD863EBC809Q37275615-03ED19B8-4758-4A13-AD48-0F8B2A93234CQ37289195-30A5EDD4-144D-49BD-AB62-14C511FB3DA3Q37298621-1BBDFCA0-F8D9-48CF-8775-711881173D86Q37299412-901FB5A0-156F-459E-AC8F-8AE9276E2D53Q37786856-8BACBAEB-F1D1-4F66-8161-55001D64F623Q37807991-8A22CDCD-8DC1-499C-ABA9-636022367A62Q37857339-80EFB2EA-E95B-43D1-82B9-4888F039E82BQ37871341-0F16EE54-CE29-4171-B6CE-B05EB0154019Q38016491-7A22407E-8EBD-4528-B970-48BA585AE095
P2860
Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Systematic review of the evide ...... nts in chronic kidney disease.
@en
Systematic review of the evide ...... nts in chronic kidney disease.
@nl
type
label
Systematic review of the evide ...... nts in chronic kidney disease.
@en
Systematic review of the evide ...... nts in chronic kidney disease.
@nl
prefLabel
Systematic review of the evide ...... nts in chronic kidney disease.
@en
Systematic review of the evide ...... nts in chronic kidney disease.
@nl
P2093
P356
P1476
Systematic review of the evide ...... nts in chronic kidney disease.
@en
P2093
Arpi Chalian
David Goldsmith
Myriam Bernal
Prajesh Kothawala
Sean Robbins
P304
P356
10.1093/NDT/GFN613
P407
P50
P577
2008-11-11T00:00:00Z